Target Ovarian Cancer's distinctive medical research programme regularly funds ovarian cancer-specific research across the whole of the UK. We fund innovative research that will benefit the largest proportion of women with ovarian cancer in the shortest timeframe. Our research strategy sets out our specific priorities for advancing research to benefit women with ovarian cancer.
In a short period of time, Target Ovarian Cancer has developed a reputation as a funder of high quality research. We have already committed over £1 million to eight outstanding projects, selected through open competition.
- Circulating tumour DNA as a specific diagnostic biomarker for ovarian cancer
- Genetic testing in epithelial ovarian cancer (GTEOC) study
- Targeting microtubules to overcome resistance to chemotherapy drugs
- Personalised therapy in ovarian cancer: targeting flap structure specific endonuclease (FEN1)
- Interleukin-6 as a therapeutic target in ovarian clear cell carcinoma
- EDMONd: Diet and nutrition for patients with inoperable malignant bowel obstruction
- Palliative chemotherapy to manage symptoms in women with recurrent ovarian cancer
- Translating our knowledge of the DNA damage response into clinical benefits for patients with ovarian cancer
Analysis by the National Cancer Research Institute has shown that there has been a 34 per cent drop in the amount spent on ovarian cancer research in the past five years, decreasing from £12.9m in 2010/2011 to £8.5m in 2015/2016.
Target Ovarian Cancer can currently only fund a small proportion of the extremely high quality proposals we receive for every grants round. There is an urgent need to substantially boost the amount we can spend on research. Fund our research.